Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Spectral Announces Third Quarter 2012 Results

Published: Friday, November 16, 2012
Last Updated: Friday, November 16, 2012
Bookmark and Share
U.S. FDA approved an amended protocol for Spectral's Phase III EUPHRATES trial.

Spectral Diagnostics Inc., has announced its financial results for the third quarter ended September 30, 2012.

Third Quarter Highlights:
• Announced that the U.S. Food and Drug Administration approved an amended protocol for Spectral's Phase III EUPHRATES trial, which will now have two planned interim analyses instead of one. Spectral requested the amendment, including the strategy for two interim analyses.

The first interim analysis, for safety, will occur when 76 randomized patients have been followed for 28 days. Seventy three patients have been randomized into the trial at 25 sites as of October 31, 2012.

The second interim analysis - anticipated in the first half of 2014 - will occur after 184 randomized patients have been followed for 28 days. At the second analysis, the Data Safety Monitoring Board will advise Spectral on the trial's safety and efficacy. Stopping rules for efficacy are included in the second interim analysis.

• Continued enrolling patients into the Company's Phase III EUPHRATES trial at a per site rate that is higher than previous sepsis trials.

Directed by the Company's Endotoxin Activity Assay (EAA™), which is the only FDA-cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is currently targeted to enroll 306 evaluable patients at up to 60 sites in North America.

Contingent on maintaining current enrolment rates and timely site start ups, the trial should be fully enrolled by the end of 2014.

• Announced an exclusive distribution agreement with Toray International Italy S.r.l. - a subsidiary of Toray Industries, Inc. - to sell the Company's Endotoxin Activity Assay in combination with Toraymyxin in Saudi Arabia and Turkey.

The expansion of commercial jurisdictions with Toray further confirms the outstanding market opportunity for the Company's unique theranostic treatment for septic shock.

• Concluded the reporting period with approximately $12.2 million in cash, cash equivalents and short- term investments.

"As the enrollment of patients in our Phase III trial progresses, we are closing in on a number of inflection points for our current and prospective investors," said Dr. Paul Walker, President and CEO of Spectral Diagnostics.

Dr. Walker continued, "In addition, there continues to be a significant unmet medical need in the area of severe sepsis, and we feel we are at the forefront of meeting that need with our theranostic treatment."

Financial Review
Revenue for the three months ended September 30, 2012 was $667,000 compared to $489,000 for the same period in the preceding year. For the nine months ended September 30, 2012 revenue was $1,942,000 compared to $1,802,000 for the same period in 2011.

For the second quarter ended September 30, 2012, the Company reported a loss of $2,077,000 compared to a loss of $1,632,000 for the corresponding period in 2011.

For the nine months ended September 30, 2012, Spectral reported a loss of $6,476,000 compared to $4,807,000 for the same period in 2011. The Company's loss was greater for the three and nine months of 2012 due to higher costs for its Phase III EUPHRATES trial.

Cash, cash equivalents and short-term investments on hand at September 30, 2012 were $12.2 million. Cash was used during the quarter ended September 30, 2012 to fund operations and for working capital purposes.

The total number of shares outstanding for the Company was 113,883,394 as at September 30, 2012.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

U.S. FDA Approves Spectral's Amended Protocol for its EUPHRATES Trial
Additional exclusion criterion added to the clinical protocol.
Thursday, June 05, 2014
Spectral Updates Status of EUPHRATES Trial
Trial to continue with a total of 650 patients.
Tuesday, April 15, 2014
Spectral Announces Fourth Quarter and Fiscal 2013 Results
Company announces fourth quarter highlights and financial review.
Tuesday, April 01, 2014
Spectral Diagnostics Provides Clinical Update on the Euphrates Trial
Company has scheduled the next DSMB meeting for early April 2014.
Thursday, March 13, 2014
Spectral Announces Status of Second Interim Analysis
DSMB evaluates the safety, efficacy and futility of Company’s EUPHRATES trial.
Friday, January 31, 2014
Spectral Announces Third Quarter 2013 Results
Company to disclose information from the second interim analysis in early 2014.
Monday, November 18, 2013
Spectral Announces Second Quarter 2013 Results
Appointment of Dr. Gualtiero Guadagni as the Company's Vice President.
Wednesday, August 14, 2013
Spectral Provides Update on its EUPHRATES Trial
Trial is on track and continues to enroll patients at an accelerated rate.
Monday, August 05, 2013
Spectral Appoints Vice President of Sales and Marketing
Appointment of Dr. Gualtiero Guadagni as the Company's Vice President.
Tuesday, July 09, 2013
Spectral Announces First Quarter 2013 Results
Company's Phase III EUPHRATES trial enrolled by the end of 2014.
Thursday, May 16, 2013
Toray Makes $5 Million Strategic Investment in Spectral Diagnostics
Private placement expected to close at the beginning of April, 2013.
Monday, March 11, 2013
Spectral Announces Results of First Interim Analysis by Data Safety and Monitoring Board
Enrolment in the EUPHRATES trial is continuing with no safety issues.
Wednesday, February 06, 2013
Spectral Announces Second Quarter 2012 Results
Spectral to double the number of trial sites for the Company's personalized medicine approach to treating septic shock.
Friday, August 17, 2012
Spectral Diagnostics Provides Update on Euphrates Trial
FDA allows Spectral to double the number of trial sites for the Company's personalized medicine approach to treating septic shock.
Monday, June 25, 2012
Spectral Announces First Quarter 2012 Results
Enrollment of patients into the Company's Phase III EUPHRATES trial.
Thursday, May 17, 2012
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos